Single Incision Laparoscopic Cholecystectomy Compared With Conventional Laparoscopic Cholecystectomy, a Randomized Controlled Clinical Study

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05728463
Collaborator
(none)
1,000
1
2
24
41.6

Study Details

Study Description

Brief Summary

Laparoscopic cholecystectomy has been accepted and is nowadays considered as the gold standard treatment of gallstones disease. Conventional laparoscopic cholecystectomy (CLC) was defined as three or four port surgery carried out with either French or American position. It reduced post-operative pain and shorten post-operative length of stay compared with open cholecystectomy in a great extent. Single-incision laparoscopic cholecystectomy (SILC) as a revolutionized surgery, the main reason for its widespread use being the following: less post-operative pain, faster recovery, better cosmetics and quicker return to full activities, all resulting in the improvement of post-operative quality of life. SILC uses the umbilicus as a natural orifice allowing easy access to peritoneal cavity, easy conversion to standard laparoscopy and its easy closure, has been widely introduced into the clinical practice for benign gallbladder diseases. SILC can easily hide the surgical scar inside the umbilicus, thus has better cosmetic effect. But the real clinical benefits for patients still remain a matter of debate. In the last 5 years, many studies on SILC have been published, trying to answer the question whether such a new approach is worthwhile or not and whether is safe and cost-effective.Based on the above controversy, we conduct a RCT comparing clinical and peri-operative outcomes, such as quality of life (QOL), of SILC and CLC with the intent to assess the actual indications of the single-incision approach.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic cholecystectomy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Single Incision Laparoscopic Cholecystectomy Compared With Conventional Laparoscopic Cholecystectomy, a Randomized Controlled Clinical Study
Actual Study Start Date :
Feb 6, 2023
Anticipated Primary Completion Date :
Feb 6, 2025
Anticipated Study Completion Date :
Feb 6, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single-incision laparoscopic cholecystectomy

SILC was defined as laparoscopic surgery done through a single trans-umbilical incision

Procedure: Laparoscopic cholecystectomy
Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.

Active Comparator: Conventional laparoscopic cholecystectomy

CLC was defined as three or four port surgery carried out with either French or American position.

Procedure: Laparoscopic cholecystectomy
Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.

Outcome Measures

Primary Outcome Measures

  1. Quality of life (time to return to normal life) [2 years]

    The quality of life of patients after operation was investigated by a unified SF-36 questionnaire.

Secondary Outcome Measures

  1. Cosmetic result [2 years]

    Evaluation of postoperative incisional scarring using the Vancouver Scar Scale

  2. Grade II or above incidence of complications [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Benign gallbladder disease
Exclusion Criteria:
  • Combined with liver cirrhosis (Child grade B and above)

  • Upper abdominal surgical history;

  • Gallbladder gangrene perforation;

  • Changes in surgical plan (conversion to laparotomy,cholangiography, bile duct exploration, bile duct injury repair, abscess clearance, multivisceral resection.)

  • patients and their families do not agree with the treatment lost follow-up

Contacts and Locations

Locations

Site City State Country Postal Code
1 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou Zhejiang China No.88 Jiefang Road

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Study Director: Daren Liu, MD, PhD, Chief Physician

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT05728463
Other Study ID Numbers:
  • 2022-0533
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 15, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Second Affiliated Hospital, School of Medicine, Zhejiang University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2023